 ASLAN Pharmaceuticals Limited Nasdaq:ASLN, TPEx:6497, a clinical-stage oncology and immunology focused biopharma company, today announced that it has priced its previously announced underwritten public offering of 5,124,527 American Depositary Shares ADSs at a public offering price of 2.50 per ADS. Each ADS represents five ordinary shares of ASLAN. The gross proceeds to ASLAN, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately 12.8 million. 